Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Phase IIB TL + YCWP + DC in Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
- Status
- TERMINATED
- Phase
- PHASE3
RTA 408 Capsules in Patients With Melanoma - REVEAL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma
- Status
- COMPLETED
- Phase
- N/A
Intratumoral Injections of LL37 for Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
- Status
- WITHDRAWN
- Phase
- PHASE1
Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Moletest Clinical Study in Scotland
- Status
- COMPLETED
- Phase
- N/A
Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
- Status
- COMPLETED
- Phase
- PHASE1
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody
- Status
- COMPLETED
- Phase
- N/A
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
- Status
- COMPLETED
- Phase
- PHASE2